Ro CEO Zach Reitano on evolving into a leading GLP-1 care platform

Ro’s evolution in healthcare

According to Business Insider, Ro CEO Zach Reitano described how the company has adapted over the past nine years as patient needs and the broader healthcare market have shifted. Ro began with direct-to-patient services and has since grown into a prominent platform for GLP-1 care, a segment gaining significant traction in consumer health.

Leadership insights in a changing market

Reitano shared insights on leading a healthcare company through rapid change during Business Insider’s The Long Play. He discussed the strategic decisions behind Ro’s shifts, including its focus on GLP-1 care, and how the company is preparing for the next phase of consumer health innovation. Reitano also reflected on the challenges of founding and scaling a company in an era of quick and unrelenting change.

What this means

Lazyfounder analysis — our interpretation, not reported fact.

Ro’s trajectory mirrors a broader trend in healthcare: the shift from generalized direct-to-patient services to specialized, high-demand care areas like GLP-1 treatments. For founders and operators in digital health, Reitano’s experience underscores the importance of adaptability—recognizing when to pivot based on market demand and patient needs. His comments also highlight the role of leadership in navigating uncertainty, a challenge familiar to many startups in regulated industries. While Ro’s focus on GLP-1 care sets it apart, the underlying strategy—building a scalable platform around a specific therapeutic area—is replicable for other companies targeting niche markets.

Related on Lazyfounder

• More health news